Travere Therapeutics
TVTX
TVTX
119 hedge funds and large institutions have $505M invested in Travere Therapeutics in 2016 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 42 increasing their positions, 43 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
119
Holders Change
+3
Holders Change %
+2.59%
% of All Funds
3.18%
Holding in Top 10
7
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-12.5%
% of All Funds
0.19%
New
20
Increased
42
Reduced
43
Closed
15
Calls
$15.1M
Puts
$35.9M
Net Calls
-$20.8M
Net Calls Change
-$41.7M
Top Buyers
| 1 |
SCM
Scopia Capital Management
New York
|
+$44.1M |
| 2 |
PA
Perceptive Advisors
New York
|
+$5.74M |
| 3 |
Goldman Sachs
New York
|
+$4.13M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.14M |
| 5 |
SIM
Spark Investment Management
New York
|
+$2.1M |
Top Sellers
| 1 |
CCM
Consonance Capital Management
New York
|
-$9.98M |
| 2 |
BNP Paribas Asset Management
Paris,
France
|
-$6.33M |
| 3 |
Barclays
London,
United Kingdom
|
-$5.91M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$3.86M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$3.37M |
